During the last session, UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares were 1.2 million, with the beta value of the company hitting 1.13. At the end of the trading day, the stock’s price was $13.10, reflecting an intraday gain of 2.02% or $0.26. The 52-week high for the URGN share is $20.70, that puts it down -58.02 from that peak though still a striking 19.08% gain since the share price plummeted to a 52-week low of $10.60. The company’s market capitalization is $551.64M, and the average intraday trading volume over the past 10 days was 0.55 million shares, and the average trade volume was 559.63K shares over the past three months.
UroGen Pharma Ltd (URGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. URGN has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UroGen Pharma Ltd (NASDAQ:URGN) trade information
UroGen Pharma Ltd (URGN) registered a 2.02% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.02% in intraday trading to $13.10, hitting a weekly high. The stock’s 5-day price performance is -5.14%, and it has moved by -11.01% in 30 days. Based on these gigs, the overall price performance for the year is -20.02%. The short interest in UroGen Pharma Ltd (NASDAQ:URGN) is 6.44 million shares and it means that shorts have 13.42 day(s) to cover.
The consensus price target of analysts on Wall Street is $43, which implies an increase of 69.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $60 respectively. As a result, URGN is trading at a discount of -358.02% off the target high and -67.94% off the low.
UroGen Pharma Ltd (URGN) estimates and forecasts
Statistics show that UroGen Pharma Ltd has underperformed its competitors in share price, compared to the industry in which it operates. UroGen Pharma Ltd (URGN) shares have gone down -12.78% during the last six months, with a year-to-date growth rate less than the industry average at 1.69% against 17.20.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.89%. While earnings are projected to return 2.16% in 2024.
URGN Dividends
UroGen Pharma Ltd is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
UroGen Pharma Ltd insiders own 9.20% of total outstanding shares while institutional holders control 93.39%, with the float percentage being 102.85%. RTW INVESTMENTS, LP is the largest shareholder of the company, while 162.0 institutions own stock in it. As of 2024-06-30, the company held over 3.56 million shares (or 10.6572% of all shares), a total value of $59.69 million in shares.
The next largest institutional holding, with 3.3 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 9.8862% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $55.37 million.
